Tumor Heterogeneity in Uveal Melanomas
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults with an incidence of 7-10/ million and has a predilection for hematogenous dissemination to the liver. Despite improvements in diagnosis and treatment of this intraocular tumor, there has not been a change in survival in the past decades. There is no effective treatment for liver metastases resulting in tumor-related death in about 45% of UM patients within 15 years after the initial diagnosis. Uveal melanoma usually arises ‘de novo’ from melanocytes derived from neural crest cells that have migrated to the epidermis and uveal tract during embryogenesis. Intraocular melanoma may arise in the choroid (70-80%), ciliary body (10-20%) and iris (5-10%). Iris melanomas are the least common and tend to present at a smaller size, probably because pigmented lesions of the iris are usually visible to the patient. Iris melanomas can cause drainage angle blockage and secondary elevation of the intraocular pressure.4 Melanomas located in the ciliary body are associated with a high metastatic potential. Choroidal melanomas compromise the majority and grow subretinal in a discoid, dome-shaped or mushroom-shaped pattern. The diagnosis is based on the clinical appearance of the tumor on ophthalmic examination. Ancillary tests include (Doppler-) ultrasonography, transillumination, fluorescein angiography and optical coherence tomography. For the diagnosis of melanoma, biopsy is reserved for tumors of uncertain origin. Conversely, tumor biopsy gains territory in vision-sparing therapies for cytogenetic analysis providing risk assessment of metastatic disease. Upon diagnosis of the primary tumor, patients are screened for metastases by liver enzyme tests and liver ultrasound. At time of diagnosis less than 2% of the patients have detectable metastases.
|Keywords||intraocular tumors, uveal melanomas|
|Promotor||Rij, G. van (Gabriel)|
|Publisher||Erasmus MC: University Medical Center Rotterdam|
|Sponsor||Alcon Nederland BV, Allergan BV, Carl Zeiss BV, Christelijke Stichting tot Praktisch Hulpbetoon Visueel Gehandicapten van alle Gezindten, D.O.R.C. International BV, Ergra Low Vision, Eyetech BV, J.E. Jurriaanse Stichting, Laméris Ootech BV, Landelijke Stichting voor Blinden en Slechtzienden, Merck Sharp & Dohme BV, MRC Holland, Novartis Pharma BV, Rotterdamse Vereniging Blindenbelangen, SWOO-Prof.dr. H.J. Flieringa and Tramedico BV.|
Mensink, H.W.. (2010, May 26). Tumor Heterogeneity in Uveal Melanomas. Erasmus MC: University Medical Center Rotterdam. Retrieved from http://hdl.handle.net/1765/19569